Cantor Fitzgerald Initiates Coverage On Opus Genetics with Overweight Rating, Announces Price Target of $15

Cantor Fitzgerald analyst Steve Seedhouse has initiated coverage on Opus Genetics (NASDAQ: IRD) with an Overweight rating. The firm has set a price target of $15 for the company's stock.